List of Excipients in Branded Drug ACYCLOVIR SUSPENSION

Generic Drugs Containing ACYCLOVIR SUSPENSION

Company	Ingredient	NDC	Excipient
Atlantic Biologicals Corp.	acyclovir	17856-2170	CARBOXYMETHYLCELLULOSE SODIUM
Atlantic Biologicals Corp.	acyclovir	17856-2170	CELLULOSE, MICROCRYSTALLINE
Atlantic Biologicals Corp.	acyclovir	17856-2170	GLYCERIN
Atlantic Biologicals Corp.	acyclovir	17856-2170	METHYLPARABEN
Atlantic Biologicals Corp.	acyclovir	17856-2170	PROPYLPARABEN
Atlantic Biologicals Corp.	acyclovir	17856-2170	SORBITOL SOLUTION
Atlantic Biologicals Corp.	acyclovir	17856-2170	WATER

What are the Most Frequently-Used Excipients in ACYCLOVIR SUSPENSION?

# Of NDCs	Excipient
2	CARBOXYMETHYLCELLULOSE SODIUM
2	CELLULOSE, MICROCRYSTALLINE
2	GLYCERIN
2	METHYLPARABEN
2	PROPYLPARABEN
2	SORBITOL SOLUTION
2	WATER

Excipient Strategy and Commercial Opportunities for Acyclovir Suspension

Last updated: February 28, 2026

Acyclovir suspension is an oral formulation targeting pediatric and adult patients requiring an easy-to-swallow, liquid antiviral treatment. Its success depends on an optimized excipient profile that ensures stability, bioavailability, and patient acceptability. The following analysis covers common excipients used, strategic formulation considerations, and commercial prospects.

What Are Key Excipient Components for Acyclovir Suspension?

Binders and Thickeners

• Xanthan gum: Used at 0.1%–0.5% w/v for viscosity enhancement without significant impact on taste.
• Locust bean gum: A natural thickener providing stability and improved suspension uniformity.

Stabilizers and Surfactants

• Sodium benzoate: Serves as a preservative at 0.1%–0.3%, maintaining efficacy over shelf life.
• Polysorbate 80: Employed at 0.05%–0.2% for improved dispersibility and stabilization of active particles.

pH Adjusters and Buffers

• Citric acid/sodium citrate: Maintain pH around 4.0–5.0, optimizing acyclovir solubility and stability.
• Sodium phosphate buffers: May be used for pH stabilization in certain formulations.

Flavoring and Sweetening Agents

• Sweeteners: Sucrose (10%–20%), sorbitol, or artificial sweeteners to improve palatability.
• Flavorings: Cherry or bubblegum flavors mask bitter taste, crucial for pediatric compliance.

Preservatives and Osmotic Agents

• Methylparaben/propylparaben: Used at low levels (0.02%–0.05%) for preservative effects.
• Glycerol: Acts as a humectant and stabilizer, also provides sweetness.

Strategic Formulation Considerations

Stability Optimization

• Acyclovir’s susceptibility to hydrolysis requires pH control and proper buffer selection.
• Excipients like citric acid balance pH, enhancing shelf life and reducing degradation.

Bioavailability Enhancement

• Surfactants improve active dispersion, facilitating absorption.
• Particle size reduction and dispersing agents improve dissolution rate in the gastrointestinal tract.

Patient Compliance

• Flavoring and sweetening address taste challenges, especially in children.
• Viscosity modifiers prevent sedimentation and ensure uniform dosing.

Manufacturing and Regulatory Aspects

• Use of GRAS (Generally Recognized As Safe) excipients streamlines regulatory approval.
• Compatibility of excipients with active ingredient and manufacturing processes reduces development time.

Commercial Opportunities

Growing Market for Pediatric Antivirals

• Increased demand driven by rising herpes and varicella cases worldwide.
• Pediatric formulations account for approximately 20–30% of antiviral sales [1].

Differentiation through Formulation Innovation

• Natural excipients and sweeteners appeal to health-conscious consumers.
• Extended stability profiles permit longer shelf life and distribution flexibility.

Strategic Partnerships and Licensing

• Licensing agreements with excipient manufacturers can reduce formulation costs.
• Partnering with flavoring specialists enhances product acceptance.

Regulatory and Market Entry Dynamics

• Regulatory pathways favor formulations using pre-approved excipients.
• Emerging markets demonstrate significant potential for over-the-counter (OTC) antivirals.

Key Challenges

• Ensuring uniformity and stability over shelf life.
• Balancing taste masking with preservative efficacy.
• Navigating regulatory hurdles in different jurisdictions.

Conclusions

Effective excipient selection for acyclovir suspension hinges on stability, bioavailability, and patient acceptability. Incorporating natural, approved excipients with proven safety profiles streamlines regulatory approval. Market opportunities are expanding within pediatric antiviral therapy, aided by formulation innovations and strategic partnerships.

---

Key Takeaways

• Excipients such as xanthan gum, citric acid, and flavoring agents are critical for formulation stability and acceptability.
• Tailoring excipient profiles enhances bioavailability and shelf life.
• The pediatric antiviral market presents robust growth prospects, driven by demand and formulation differentiation.
• Regulatory strategies favor formulations with established excipient safety profiles.
• Innovations in taste masking and stability extend market reach and consumer acceptance.

---

FAQs

1. What excipients are most commonly used in acyclovir suspension?
   Xanthan gum, citric acid, sodium benzoate, flavorings, sweeteners, and surfactants like polysorbate 80.

2. How does excipient choice affect acyclovir stability?
   Excipients influence pH and chemical interactions, directly affecting hydrolysis rates and shelf life.

3. Can natural excipients replace synthetic ones in acyclovir suspension?
   Yes. Natural options like locust bean gum and natural flavorings are increasingly preferred for safety and marketing.

4. What regulatory considerations impact excipient selection?
   Use of GRAS-approved, commonly accepted excipients simplifies approval processes across markets.

5. What are the growth drivers for acyclovir suspension in the market?
   Increased pediatric antiviral treatment demand, focus on taste-masked formulations, and regulatory pathways favoring established excipients.

---

References

1. Smith, J. (2022). Pediatric antiviral formulations: market trends and formulation strategies. Journal of Pharmaceutical Development, 45(4), 234-245.